Cheryl Pegus, Director at BOSTON SCIENTIFIC CORP (BSX), bought 1,770 shares at $56.49 ($100K) on 2026-05-20, disclosed to the SEC on 2026-05-21.
Director Cheryl Pegus purchased 1,770 shares for roughly $100k, marking the largest insider purchase in Boston Scientific's history. This aggressive buying occurs as the stock has fallen 23.4% over the last 90 days, suggesting insiders see value near the 52-week low.
BSX is currently trading at $57.13, down 23.4% over the last 90 days and sitting 47.83% below its 52-week high of $109.50.
Positive trial results for the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter were reported on May 20. Management is pushing to expand the WATCHMAN addressable market from 5M to 20M patients, as noted in news on May 26. The purchase of 1,770 shares by Director Cheryl Pegus represents the largest insider purchase in the company's history.
BofA cut the price target to $68 from $105 on May 18, citing concerns regarding the broader medtech sector. The company faces ongoing recalls of its LUX-Dx II arrhythmia detector devices, as reported on May 26.
Something here stands out, but not much.
| Filing → |
| PHR | SELL | 2019-07-24 | $5.1M | — | Filing → |
| TCMD | BUY | 2017-12-14 | $28K | — | Filing → |